Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Stem cell library screen identified ruxolitinib as regulator of osteoblastic differentiation of human skeletal stem cells

Fig. 3

The effect of ruxolitinib on osteoblastic differentiation of hBMSCs. a hMSCs were induced into osteoblasts for 21 days in the absence (left panel) or presence (right panel) of ruxolitinib and were stained for mineralized matrix formation using Alizarin Red stain. Images were taken at × 10 magnification using a Zeiss inverted microscope. Quantitative RT-PCR analysis for gene expression of alkaline phosphatase (ALP) and RUNX2 in hBMSCs inducted into osteoblasts for 10 days (b) or 21 days (c) in the absence (blue) or presence (red) of ruxolitinib. Cells treated with DMSO were used as control. Gene expression was normalized to β-actin. Data are presented as mean fold change ± SEM (n = 6) from two independent experiments. ***P ≤ 0.0005. Abbreviations: ALP alkaline phosphatase, RUNX2 runt-related transcription factor 2, DMSO dimethyl sulfoxide

Back to article page